Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
maverick_1 reposted
Gregory Zivic, MD
@metacollectiveG
$NWBO We will beat MMs. I believe we’ll see at least a couple hundred million immediately when first 3 just fold. What LP has done on fumes will suddenly be explosive with that cash. FlaskWorks $2 bn, in the UK/Canada market. Squeeze like what rocketed $TSLA. All before year end
Peter Davis
@peter_brit
·
5h
#dcvax $nwbo #gbm
Quote
Gregory Zivic, MD
@metacollectiveG
·
16h
Replying to @RickHancock17
I’m just trying to clear the weeds away. I am not an investment advisor and have never been one to gamble. I’ve been to a casino twice in my life. I know this science like the back of my hand and I believe it’s beyond anything seen in Medicine before
Thanks Captain.
GLTU
100% agree Doc logic.
GLTU
evanstony,
Agree with you on that.
That is why it is of the utmost importance that at an R/S more extremely important things are said, the most important of which is a lot of money.
We now know that wonderful press releases have little effect with the mafia scum breathing down our necks.
GLTU
evanstoy,
The total value of your portfolio remains the same before and after the split.
Example: before the split you have 20,000 shares of, for example, $1.
Your portfolio is therefore worth $20,000.
After the split(1;20) you still have 1000 shares left, but these shares are now worth $20 each.
Your portfolio is still worth $20,000.
GLTU
Atilla,
Linda F Powers is the 10 percent owner of INmune Bio Inc. Other key executives at INmune Bio Inc include 10 percent owner & CFO & Treasurer & Secretary David J Moss , 10 percent owner & Chief Scientific Officer Mark William Lowdell , and director & 10 percent owner & President & CEO Raymond Joseph Tesi .
https://www.google.com/search?q=What+is+the+relationship+between+Inmune+bio+and+Linda+Powers+%3F&sca_esv=8276d79fd9a4c5db&sca_upv=1&rlz=1C1CHBD_nlNL901NL901&sxsrf=ADLYWILebNWntOaq1gH_dKadkn9PoaT7mQ%3A1716375574709&ei=FtBNZqLpKr3pi-gPrJKMuAU&ved=0ahUKEwiizLmjjaGGAxW99AIHHSwJA1cQ4dUDCBA&uact=5&oq=What+is+the+relationship+between+Inmune+bio+and+Linda+Powers+%3F&gs_lp=Egxnd3Mtd2l6LXNlcnAiPldoYXQgaXMgdGhlIHJlbGF0aW9uc2hpcCBiZXR3ZWVuIElubXVuZSBiaW8gYW5kIExpbmRhIFBvd2VycyA_SABQAFgAcAB4AZABAJgBAKABAKoBALgBA8gBAPgBAZgCAKACAJgDAJIHAKAHAA&sclient=gws-wiz-serp
GLTU
I see that you have been running through this board for 3 months and still have no idea what has happened in the past that has forced management to adjust its strategy.
Extensive attention has also been paid here to the lawsuit and its cause, M/M against the criminality of Wall Street.
The necessary evidence (spoofing) has already been provided.
The price has been manipulated for 8 years and you are just talking about a price drop in the last 5 months and the management that you do not like.
If it hadn't been for them (and I'm sure you know that just like all the other board visitors) we wouldn't be here now and your visit would also have been unnecessary.
Stop your nonsense and don't think that your careful switch from long to bash has gone unnoticed.
Welcome to the ignore list.
Richard Fairgrieve
@RichFairgrieve
·
May 17
Hmmm... Doesn't he have cancer? Isn't this where along with Sawston $DCVax is made? Isn't King's where Dr. Keymours Ashkan, the leading expert on $DCVax is based? Interesting to say the least.
Quote
King's College London
@KingsCollegeLon
·
May 16
We are delighted that His Majesty The King has become our Royal Patron, continuing a long and valued association between the University and The Monarch.
Read more ⬇️
https://kcl.ac.uk/news/his-majesty-the-king-becomes-patron-of-kings-college-london
Show more
Thank you Doclogic for the nice short summary.
" All cause mortality was 5%+ more with subcutaneous administration vs traditional IV. Not really something being hoped for when doing the study. OS not reported nor PFS ".
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174444064
GLTU
As you can see ASCO starts may 31.
https://conferences.asco.org/am/attend
GLTU
Thanks flipper.
Just to let everyone know:
Single stock :
' I wonder how early diagnosis plus early DCVAX with no Chemo would impact OS".
Flipper: A lot, imo. Particularly when 5-ala used during surgery.
" 5-ALA is a compound (swallowed by the patient before the surgery, in a liquid solution) that causes malignant glioma cells to fluoresce ".
https://www.google.com/search?q=What+is+5-ala+used+during+surgery+%3F&rlz=1C1CHBD_nlNL901NL901&oq=What+is+5-ala+used+during+surgery+%3F&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigATIHCAIQIRigATIHCAMQIRigATIHCAQQIRigAdIBCjIyODQ1ajBqMTWoAgiwAgE&sourceid=chrome&ie=UTF-8
Right you are ilovetech.
GLTU
Horse4CarT, you wrote :
" They not only mark the close imo, they basically script the whole daily sp routinely.
Market open - sp goes up early 1-2 cents
Midday - slow walk down of sp
Into close - close to unchanged or a little up or down, occasionally moving the sp more to vary things and work the emotional trading.
I’m sure I’m not the only one who has become numb to the pattern imo ".
Here again a clear case of stock price manipulation.
But don't think this kind of thing doesn't happen on the Nasdaq.
I have also suffered a few blows with shares there (fortunately I also had a number of profits) in the same way as NWBO shares are manipulated.
But look at Nevercure. From $12 to $22 within 1 month!
And on what? Because they had a little less loss? Or because they were going to give 20 presentations? And what other nonsense? Just nonsensical pumping.
Pure manipulation to then shorten the retailer's wings with increases in shareprice with low volumes to longing investors who think they have got something nice :). A completely hopeless company that is on the verge of the end in sight. Then have the BOD of their friends (nevercure) dump large numbers at these higher prices.
Repeat and divide the loot later.
Manipulation with the big loser: retail!
I hope Milstein and Cohen will have the start of finishing this scum.
Best to you.
Peter Davis
@peter_brit
·
1h
#dcvax $nwbo #gbm
Quote
Gregory Zivic, MD
@metacollectiveG
·
13h
Replying to @metacollectiveG and @StonkMasterJ
Les was listing a number of things he felt would be coming together near of soon after Approval of the MAA including in-licensing deals, combos, law suit, and FlaskWorks certification. He meant that “later in the fall” he’d be able to confirm all of these clearly.
Claes Norgaard
@Cleves_trades
·
12h
I have to disagree, why would they say validation was passed on January 24th?
I believe the 80 days fase 1 is long done with no stop clock and we are in the final 70 days now.
In my opinion June 22nd is the date (150 days from Jan 24th) and funny enough just in time for the asm😉
hoffmann6383
@hoffmann6383
·
12h
You could be right. I'm admittedly confused on the January 24th versus March 7th date. I went with March 7th to be on the conservative side.
Thank you dstock.
Appreciated.
GLTU
dstock, thanks for your post.
You wrote about keytruda : "What happened to Merck's SC keytruda? I don't remember TLD from the p3 trial has been released yet ".
I assume you are talking about the trial that started in 2020:
https://clinicaltrials.ucbraid.org/trial/NCT04201873 at UCLA.
DCvax (+poly-ICLC, outpatient clinic already added to the DCvax formula) functions as a placebo arm and DCvax (+poli) + Keytruda as the treatment arm.
So we are looking here to see whether Keytruda can add anything to the fantastic results of DCvax+ poly that we saw in the Nature article.
The study is for rGBM.
The first results should be seen in Jan.2024.
GLTU
If this is indeed the case, Merck will be extra happy, but I think so will we.
And especially the patients with rGBM. Then we are closer to a complete cure for rGBM.
If that is not the case, Merck will have a major problem in 2028 when the Keytruda patent expires.
I must say that I am very curious and hope that we will see the results soon (perhaps only after MHRA approval).
Post
See new posts
Conversation
Peter Davis
@peter_brit
·
May 11
#dcvax $nwbo #gbm
After the amazing DCVax/Poly-ICLC's combination results peer-reviewed in Nature and the excellent prostate cancer results using Poly-ICLC, it begs to question whether plans will be made for a combination of DCVax and Poly=ICLC for prostate cancer bearing in…
Show more
Gregory Zivic, MD
@metacollectiveG
$NWBO I believe a Prostate trial with Poly ICLC is in the works and we’ll know before year’s end. It just makes sense; large market, already have an approved trial with DCVax. Now add Dr. Liau’s paper and LP’s foresight 2 years ago and presto…
Peter Davis
@peter_brit
#dcvax $nwbo #gbm
I still have not seen anything to suggest that Project Orbis might still not be in play. The company would not necessarily say if it was but interesting that the rapid assessment procedure of 150 day does not rule out Orbis from being in play, just a thought.....
The fact they have not made any "amendment or addition to its MAA after the original 12/20/2023 submission” is the only barrier however to be considered for the Project Orbis pathway it is possible that the following might have applied "Project Orbis Partners (POPs) may propose products for inclusion in the scheme. " so the company statement could still be valid if MHRA proposed the company's inclusion for Orbis pathway.
I am reminded of a conversation a poster had with DI where he stated when he was asked about UK being the first to approve, DI's response was "not necessarily"
Linda Powers is on record as stating that with regards to Marketing Authorization applications that they would be "Strategic"...
https://gov.uk/guidance/guidance-on-project-orbis
https://ih.advfn.com/stock-market/USOTC/northwest-biotherapeutics-qb-NWBO/stock-news/93828655/form-10-q-quarterly-report-sections-13-or-15d
Thanks again Captain.
GLTU
And at least 5 overhere!
GLTU
Me too.
GLTU
Peter Davis reposted
UCLA Neurology
@UCLANeurology
The UCLA Brain Tumor Center is hosting the 24th Annual UCLA Brain Tumor Conference on Friday, May 10, and Saturday, May 11!
Join patients & healthcare professionals at this free conference to hear the latest news on brain tumors, resources, and more! http://uclahealth.org/braintumor
Peter Davis reposted
kristen shaughnessy
@kshaughnessy2
The CAT system is designed to protect against illegal trades. Ask yourself why some are fighting so hard against it while claiming to protect "retail investors" ?
"After 14 years of debate, the Securities and Exchange Commission is in the final stages of bringing a powerful new surveillance tool fully online. But Wall Street is seizing on the ideal political environment for a last-ditch attempt to kill it.
The Consolidated Audit Trail is a database, one of the largest ever created, that is set to revolutionize how the agency monitors trading activity and spots potential misconduct. ..."
https://bloomberg.com/news/articles/2024-05-02/citadel-securities-leads-suit-to-gut-sec-trading-surveillance
Gregory Zivic, MD
@metacollectiveG
$NWBO The Eden version of the automated dendritic cell manufacturing process will be worth at least $20 billion. It’s versatility in being able to create not just #DCVax but other DC based treatments is beyond anything seen in Biotech to date. I believe a C suite can handle 5-8
5:08 PM · May 3, 2024
·
655
Views
First see then believe ilovetech.
GLTU
Thank you Truthfan.
GLTU
Well done tryn2 !
GLTU
I was one of the lucky ones who was able to buy a mountain of shares at 14 and 15 cents in 2017.
GLTU
Nevercure.
I think they have gone insane at Pharmakon Advisors.
https://finance.yahoo.com/news/novocure-secures-400-million-multi-110100912.html
Spartex,
A while ago we had a person here on the board, basher,
whose nickname was Dr.Lowenstein.
I suspect he is now spewing his filth here under a different name.
GLTU
It is particularly noteworthy that a Dr. Lowenstein is mentioned at the beginning of the Article :):):)
GLTU
Thanks Captain.
GLTU
Captain,
It was Smokey if I'm not mistaken a few days ago.
According to him, it was most likely the exercise of the warrants that increased the outstanding number of shares.
I can't find his post about this at the moment.
GLTU
Together they form a large platform!
GLTU
Thanks Captain.
GLTU
We are on the cusp of recognition of a treatment for many (if not all) types of cancer that is unprecedented and on the verge of quickly becoming a cure. With "simply a vaccine". Not a toxic gang.
Can we compare it with other discoveries in the medical world?
Antibiotics maybe?
In any case, it will help many millions of people.
Eve!
And unfortunately there are longs here on the board who have waited years for this recognition and now want to flee?
And why? Because the price ends in the red almost every day?
They are being kicked around by a bunch of criminals who will most likely get their well-deserved reward in the foreseeable future: prosecution and striped suits. Creating pure frustration at longs.
All milestones required to exploit the product have been virtually delivered by Linda Powers, Linda Liau, Dr.Bosch and many others.
An incredible achievement to have repelled all attacks from various sides for almost 9 years (after the 'farewell' of Mr. Woodford) and to have found many solutions (to major problems) that none of us could have come up with.
Powers is brilliant!
How is it possible that after waiting 10 years there are people who cannot endure another few months, a few weeks or even shorter?
It seems that the criminals' tactics have already claimed some victims.
Pity.
Peter Davis
@peter_brit
#dcvax $nwbo #gbm
I looked again at the 'hit piece' and forced correction of the article by Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca. As my post referenced below, there were in fact a number of other false claims made which were not addressed by these authors however, I found it of particular interest that not only was the 'hit piece' the 'editor's choice' but actually when you click on the correction there is something really interesting. It appears they grudgingly corrected just one of a number of flawed and incorrect statements but in sheer desperation to continue negativity towards DCVax results, on the same correction article they have a list of four 'Recommended' articles, three of which are 'hit pieces' against DCVax:-
Recommended:
First results on the DCVax phase III trial: raising more questions than providing answersWolfgang Wick et al., Neuro-Oncology, 2018
https://academic.oup.com/neuro-oncology/article/20/10/1283/5077256?itm_medium=sidebar&itm_source=trendmd-widget&itm_campaign=Neuro-Oncology&itm_content=Neuro-Oncology_0
Dendritic cell vaccine trials in gliomas: Untangling the linesKelly M Hotchkiss et al., Neuro-Oncology
https://pubmed.ncbi.nlm.nih.gov/37289203/
This obvious bias got me to question who was the Editor in question and it turns out to be Susan M Chang who is the editor-in-chief, her profile attached below is very telling. Couple this along with the fact that Matthias Preusser (an author of another DCVax hit piece) is executive editor, E Antonio Chiocca Associate editor(author of hit piece and forced to correct) also:
Martin J. van den Bent,John de Groot, David A. Reardon and Susan Short, who have all co-authored 'hit pieces' against DCVax are on the Editorial Board
Not only serious attempts to attack DCVax's results but a coordinated attack it seems all from one journal and assisted by the editor-in-chief. Not on of these Doctors found anything wrong with the original article ? 🤔
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 29, 2023
In a nutshell...
I asked Microsoft's AI to provide the following response to the article by Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca
Thank you for your question. I have analysed and commented on the article by Chen…
#dcvax $nwbo #gbm
— Peter Davis (@peter_brit) April 12, 2024
Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma
Published: 05 April 2024
Hilarious.. In this recent article the authors grudgingly accept that "DCVax-L in recurrent and newly diagnosed GBM reported a survival benefit"but… pic.twitter.com/DAP4wYZeuI